fevereiro 01, 2019

Cosentyx is a human interleukin-17A antagonist

According to pooled data from four Phase 3 estudos, tratamento com secukinumab (Cosentyx; Novartis) was associated with improvement in mobility, self-care, and usual activities (e.g., work, estudo, housework, family or leisure activities) when compared with placebo in patients with moderate-to-severe plaque psoriasis.

No ERASURE, ELÉTRICO, CARACTERÍSTICA, e ensaios de junção, psoriasis patients who reported problems in these quality of life measures (through the EQ-5D-3L questionnaire) were randomized to receive secukinumab 300mg or placebo and were assessed at weeks 4, 8, e 12. Results showed that at week 4, the percentage of patients reporting no problems in mobility (60.7%), self-care (71.4%), or change in usual activities (63.8%) was higher in the secukinumab group than in the placebo arm (38.5%, 40.9%, e 31.1%, respectivamente); similar trends were observed at week 8 e 12.

“Moderate-to-severe plaque psoriasis can impact every aspect of a person’s life,” stated Steven R. Feldman, MD, PhD, Wake Forest School of Medicine. “These findings suggest that helping patients feel better through improved quality of life and ability to function should be a goal as important as skin clearance in psoriasis management.”

Cosentyx, a human interleukin-17A antagonist, is FDA-approved for the treatment of: moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy; adults with active psoriatic arthritis; and adults with active ankylosing spondylitis.

siga @DermAdvisor

Para mais informações visite Novartis.com.